- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03317223
A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients
October 8, 2021 updated by: HK inno.N Corporation
A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Triple Therapy With CJ-12420, Amoxicillin and Clarithromycin in H. Pylori Positive Patients
The current study is designed to demonstrate the non-inferiority of CJ-12420-based triple therapy (CJ-12420, amoxicillin and clarithromycin) versus lansoprazole-based triple therapy (lansoprazole, amoxicillin and clarithromycin) in H. pylori eradication rate and to evaluate the safety of CJ-12420 following oral administration of either triple therapy twice daily for 7 days in H. pylori positive patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a double blind, randomized, active controlled, phase 3 study. Subjects will be randomly assigned to one of the two treatment groups (CJ-12420 50mg, lansoprazole 30mg). All subjects will be asked to take 5 tablets include clarithromycin, amoxicillin twice a day for 7 days.
After the treatment, UBT test will be conducted to confirm the Helicobacter pylori eradication.
Study Type
Interventional
Enrollment (Actual)
350
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 03722
- Yonsei University Severance Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- H. pylori-positive at screening
- Complain of gastric discomfort symptom
Exclusion Criteria:
- Having received prior therapy for eradication of H. pylori
- Prior use of proton pump inhibitors (PPIs), H2 receptor blockers, at a full dosage within 14 days
- Prior use of H. pylori eradication effective antibiotics, bismuth within 14 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CJ-12420/Clarithromycin/Amoxicillin
CJ-12420 50mg /Clarithromycin 500mg /Amoxicillin 1g
|
CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
Other Names:
|
Active Comparator: Lansoprazole/Clarithromycin/Amoxicillin
Lansoprazole 30mg /Clarithromycin 500mg /Amoxicillin 1g
|
CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
H. pylori eradication rate
Time Frame: twice a day
|
Subjects will be considered to succeed in achieving H. pylori eradication if subject's UBT test (Eradication Assessment)
|
twice a day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yong Chan Lee, Severance Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 17, 2017
Primary Completion (Actual)
January 21, 2019
Study Completion (Actual)
January 24, 2019
Study Registration Dates
First Submitted
October 18, 2017
First Submitted That Met QC Criteria
October 18, 2017
First Posted (Actual)
October 23, 2017
Study Record Updates
Last Update Posted (Actual)
October 18, 2021
Last Update Submitted That Met QC Criteria
October 8, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Protein Synthesis Inhibitors
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Lansoprazole
- Amoxicillin
- Clarithromycin
Other Study ID Numbers
- CJ_APA_306
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Helicobacter Pylori Infection
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingHelicobacter Pylori Infection | Helicobacter Pylori EradicationBangladesh
-
Shandong UniversityRecruitingHelicobacter Pylori Infection | Patient Education | Helicobacter Pylori EradicationChina
-
Shandong UniversityCompletedHelicobacter Pylori Infection Helicobacter Pylori Eradication Patient EducationChina
-
Shanghai Jiao Tong University School of MedicineCompletedCure Rate of Helicobacter Pylori InfectionChina
-
Seoul National University Bundang HospitalRecruitingHelicobacter Pylori Infection | Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation | Helicobacter Pylori Associated Gastrointestinal Disease | Helicobacter Pylori Infection, Susceptibility toKorea, Republic of
-
The First Affiliated Hospital of Nanchang UniversityUnknownBacterial Infection Due to Helicobacter Pylori (H. Pylori) | Eradication Therapy of Helicobacter Pylori | Detection of Helicobacter PyloriChina
-
Tanta UniversityNot yet recruitingPersistent Helicobacter Pylori InfectionEgypt
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedHelicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)Helicobacter Pylori Infection | Helicobacter Pylori gyrA Levofloxacin Resistance Mutation | Fecal Drug Resistance Gene Detection | Helicobacter Pylori Infection, Susceptibility toChina
-
National University Hospital, SingaporeUnknownHELICOBACTER PYLORI INFECTIONSSingapore
-
Kaohsiung Veterans General Hospital.Kaohsiung Medical University Chung-Ho Memorial HospitalCompletedHelicobacter Pylori InfectionTaiwan
Clinical Trials on CJ-12420/Clarithromycin/Amoxicillin
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
HK inno.N CorporationCompletedErosive EsophagitisKorea, Republic of
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
HK inno.N CorporationAsan Medical CenterCompleted
-
HK inno.N CorporationCompletedNon-erosive Reflux DiseaseKorea, Republic of
-
HK inno.N CorporationCompletedTo Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose AdministrationDrug Interaction | Pharmacokinetic | PharmacodynamicKorea, Republic of
-
HK inno.N CorporationCompleted
-
HK inno.N CorporationCompletedErosive EsophagitisKorea, Republic of
-
HK inno.N CorporationCompletedGastric UlcerKorea, Republic of
-
HK inno.N CorporationCompletedGERD | Erosive EsophagitisKorea, Republic of